The BRIMM project is a multi-site breast cancer study using intravoxel incoherent motion (IVIM) MRI to develop a robust, cross-platform imaging biomarker that noninvasively characterizes the tumor microenvironment and predicts response to neoadjuvant chemotherapy.
This project investigates REFMAP, an advanced diffusion MRI approach combining IVIM and DTI, to noninvasively diagnose kidney tumors, estimate glomerular filtration rate, and predict renal function outcomes following surgery.